Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | SGK1 | O00141 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 2/20 | 0.31 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.31 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | FADS1 | O60427 | 1/20 | 0.30 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588668 | 0.88 | LRRK2 (0.35) | LRRK2SGK1BRD4METAP2PTGS2 | |
| SCHEMBL589706 | 0.80 | JAK2 (0.43) | LRRK2SGK1SCD | |
| SCHEMBL589780 | 0.80 | BRD4 (0.36) | BRD4 | |
| SCHEMBL589152 | 0.79 | TUBB3 (0.32) | — | |
| SCHEMBL589060 | 0.75 | SGK1 (0.34) | SGK1 | |
| SCHEMBL2873675 | 0.74 | PAK1 (0.48) | LRRK2MAP2K7MAP2K4PTGS2PAK1 | |
| SCHEMBL31672493 | 0.74 | PAK1 (0.48) | LRRK2MAP2K7MAP2K4PTGS2PAK1 | |
| SCHEMBL589290 | 0.72 | HAO1 (0.34) | LRRK2SGK1 | |
| SCHEMBL31672408 | 0.71 | KDR (0.47) | MAP2K4 | |
| SCHEMBL10151215 | 0.71 | KDR (0.47) | MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | claimed |
| EP-2311825-A1 | Pyrimidineamines as angiogenesis modulators | GlaxoSmithKline LLC (US) | 2011-04-20 | — | — | EP | claimed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | claimed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | claimed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-20120277258-A1 | Chemical Compounds | LEO OSPREY LIMITED (JE) | 2012-11-01 | — | — | US | disclosed |
| US-8114885-B2 | Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer | GLAXOSMITHKLINE LLC (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2311825-A1 | Pyrimidineamines as angiogenesis modulators | GlaxoSmithKline LLC (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7858626-B2 | Pyrimidineamines as angiogenesis modulators | GLAXOSMITHKLINE LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-04-29 | — | — | US | disclosed |
| US-20070292513-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-12-20 | — | — | US | disclosed |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-11-22 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-7105530-B2 | inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | TYMS, TYMP, DPYD | LRRK2 2996/4885SGK1 4755/4885BRD4 604/4885 |
| US-20070015756-A1 | Chemical compounds | KDR, FLT4, FLT1 | LRRK2 1736/4885SGK1 2944/4885BRD4 594/4885 |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | LRRK2 1736/4885SGK1 2944/4885BRD4 594/4885 |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | LRRK2 377/4885SGK1 204/4885BRD4 1292/4885 |
| US-20120277258-A1 | Chemical Compounds | KDR, FLT4, FLT1 | LRRK2 1736/4885SGK1 2944/4885BRD4 594/4885 |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | LRRK2 1736/4885SGK1 2944/4885BRD4 594/4885 |
| US-20070292513-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | LRRK2 1736/4885SGK1 2944/4885BRD4 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.